Covidien pulls single-use insulin syringes from U.S. stores

11/6/2008 | Reuters

The FDA announced Wednesday that Covidien is voluntarily withdrawing almost half a million ReliOn syringes that could have been mislabeled during packaging. The syringes could cause insulin overdose in diabetics, resulting in low glucose levels and adverse reactions including death, the agency warned. Covidien has asked retailers to eliminate affected products from their inventory and put them in quarantine.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA